<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">Arq. Bras. Cardiol.</journal-id>
      <journal-title-group>
        <journal-title>Arquivos brasileiros de cardiologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24714790</article-id>
      <article-id pub-id-type="pmc">3987316</article-id>
      <article-id pub-id-type="doi">10.5935/abc.20140024</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Sildenafil for Noncompaction Cardiomyopathy Treatment in a Child: Case
Report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Redondo</surname>
            <given-names>Ana Carolina Costa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fuenmayor</surname>
            <given-names>Gabriela</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shiraishi</surname>
            <given-names>Karen Saori</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fontes</surname>
            <given-names>Simone Rolim F</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Elias</surname>
            <given-names>Patr&#xED;cia Figueiredo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Souza</surname>
            <given-names>Rogerio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jatene</surname>
            <given-names>Ieda Biscegli</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> Hospital do Cora&#xE7;&#xE3;o - Associa&#xE7;&#xE3;o do Sanat&#xF3;rio S&#xED;rio, S&#xE3;o Paulo, SP -
Brazil </aff>
      <aff id="aff02"><label>2</label> Instituto do Cora&#xE7;&#xE3;o, Hospital das Cl&#xED;nicas da Faculdade de Medicina da
Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, SP - Brazil </aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing Address: Ieda Biscegli Jatene</bold>, Rua Des. Eliseu Guilherme, 123,
CEP 04004-020 Para&#xED;so, S&#xE3;o Paulo, SP - Brasil. E-mail:
<email>ijatene@hcor.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2014</year>
      </pub-date>
      <volume>102</volume>
      <issue>3</issue>
      <fpage>27</fpage>
      <lpage>30</lpage>
      <history>
        <date date-type="received">
          <day>05</day>
          <month>2</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>02</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>7</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>Heart Failure</kwd>
        <kwd>Cardiomyopathy, Dilated / complications</kwd>
        <kwd>Phosphodiesterase Inhibitors</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Congestive heart failure (CHF) occurs when the heart can no longer maintain the baseline
metabolic demand triggered by physiological venous pressure. In the pediatric
population, it corresponds to a complex entity with multiple etiologies, depending on
the age group assessed, being mainly associated with congenital structural
malformations, cardiomyopathies, or secondary to arrhythmogenic, infectious, ischemic,
toxic or infiltrative events<sup><xref rid="r01" ref-type="bibr">1</xref></sup>.</p>
      <p>The incidence of CHF in children also varies according to the underlying condition,
ranging from 15% to 25% in patients with congenital heart defects. In structurally
normal hearts, cardiomyopathy is the major factor associated with CHF, with a 40%
incidence of CHF reported in those patients<sup><xref rid="r01" ref-type="bibr">1</xref></sup>.</p>
      <p>Isolated noncompaction cardiomyopathy is a rare disease, whose incidence in the general
population ranges from 0.014% to 1.3%. It might result from a failure in compaction of
the ventricular myocardium between weeks 5 and 8 of the embryonic life, leading to the
persistence of myocardial trabeculations and deep recesses, which communicate with the
ventricular cavity, generating myocardial thickening in two distinct layers (compacted
and noncompacted). Initially reported in the pediatric population or with a congenital
cardiopathy, it also affects adults with no other heart disease<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup>.</p>
      <p>This failure in the regression of embryonic sinusoids is postulated to be due to the
extremely high pressures that the ventricles undergo in that developmental period.
However, the literature has reported a genetic aspect emphasizing the relationship of
the disease with different genes, such as the mutation of gene G4.5 in families with
severe infantile noncompaction cardiomyopathy, mutations P121L, CYPHER/ZASP, E101K, and
a locus containing the disease gene in chromosome 11p15<sup><xref rid="r03" ref-type="bibr">3</xref></sup>.</p>
      <p>The major complications of patients with noncompaction cardiomyopathy are pulmonary
thromboembolism, arrhythmias and CHF<sup><xref rid="r03" ref-type="bibr">3</xref></sup>.
In addition to the usual treatment of CHF, new classes of drugs, such as the
phosphodiesterase type 5 (PDE-5) inhibitors, have been studied<sup><xref rid="r04" ref-type="bibr">4</xref></sup>. They are currently used for the treatment of erectile
dysfunction and pulmonary arterial hypertension, and began to be studied for the
treatment of CHF after the demonstration of higher PDE-5 expression in myocytes and
vascular muscle cells, as well as of markers of oxidative stress in patients with
CHF<sup><xref rid="r05" ref-type="bibr">5</xref></sup>.</p>
      <p>We report, for the first time, the clinical and laboratory findings of a patient with
noncompaction cardiomyopathy after the addition of sildenafil (PDE-5 inhibitor) to the
usual treatment.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>The patient is a 6-year-old male, previously healthy, admitted with clinical findings
compatible with CHF. The clinical investigation ruled out causes of CHF secondary to
infectious, arrhythmogenic, infiltrative, toxic and ischemic processes and neuromuscular
disorders. The serum level of type B natriuretic peptide (BNP) was 641 pg/mL. The
echocardiographic findings were as follows: left ventricular (LV) ejection fraction of
19.1%; significant biventricular systolic dysfunction; LV diastolic dysfunction;
significant LV dilation; and mild left atrial dilation. In addition, deep myocardial
trabeculae were observed, communicating with the free LV cavity, with a noncompaction to
compaction ratio of 3.2:1 and no structural malformation, establishing the diagnosis of
bilateral cardiomyopathy of the noncompaction myocardial type (<xref ref-type="fig" rid="f01">Figure 1</xref>). Drug treatment with angiotensin-converting-enzyme
inhibitor (ACEI), diuretics and carvedilol was initiated.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Echocardiographic study performed at the age of 6 years shows dilated left
chambers, spongy left ventricle, and noncompacted to compacted myocardium ratio of
3.2:1, long axis plane (A) and short axis plane (C), and after 7 years of clinical
drug treatment (B and D).</p>
        </caption>
        <graphic xlink:href="abc-102-03-0e27-g01"/>
      </fig>
      <p>After one year of clinical follow-up and optimized pharmacological treatment (diuretics,
ACEI and beta blocker), his symptoms and functional class worsened, a new hospital
admission being necessary. Echocardiography showed persistent dilated cardiomyopathy of
significant hemodynamic repercussion, with moderate tricuspid and mild mitral
regurgitations. Because of the unfavorable diagnosis and clinical course, the patient
was assessed aiming at heart transplantation. The hemodynamic evaluation showed
cardiomyopathy with noncompaction of the ventricles and spongy myocardium, normal
capillary angiography and mean capillary pressure of 25 mm Hg.</p>
      <p>Rescue therapy with sildenafil at the dose of 2 mg/kg/day was indicated while awaiting a
donor. The clinical and imaging follow-up every three months showed progressive
improvement, with normalization of the ventricular function, of the BNP serum levels and
of the symptoms (<xref ref-type="table" rid="t01">Table 1</xref>). The patient was then
removed from the heart transplantation list, maintaining good quality of life.</p>
      <table-wrap id="t01" orientation="portrait" position="float">
        <label>Table 1</label>
        <caption>
          <p>Description of the clinical, laboratory and echocardiographic parameters before
and after the Introduction of sildenafil In the drug treatment</p>
        </caption>
        <table frame="hsides" rules="rows">
          <thead>
            <tr align="center">
              <th rowspan="1" colspan="1">&#xA0;</th>
              <th rowspan="1" colspan="1">
<bold>Before sildenafil</bold>
</th>
              <th rowspan="1" colspan="1">
<bold>During sildenafil administration</bold>
</th>
              <th rowspan="1" colspan="1">
<bold>After sildenafil administration</bold>
</th>
            </tr>
          </thead>
          <tbody>
            <tr align="center">
              <td align="left" rowspan="1" colspan="1"> HR (bpm) </td>
              <td rowspan="1" colspan="1"> 100 </td>
              <td rowspan="1" colspan="1"> 80 </td>
              <td rowspan="1" colspan="1"> 79 </td>
            </tr>
            <tr align="center">
              <td align="left" rowspan="1" colspan="1"> SaO<sub>2</sub> (%) </td>
              <td rowspan="1" colspan="1"> 90 </td>
              <td rowspan="1" colspan="1"> 99 </td>
              <td rowspan="1" colspan="1"> 99 </td>
            </tr>
            <tr align="center">
              <td align="left" rowspan="1" colspan="1"> Functional class </td>
              <td rowspan="1" colspan="1"> III </td>
              <td rowspan="1" colspan="1"> II </td>
              <td rowspan="1" colspan="1"> I </td>
            </tr>
            <tr align="center">
              <td align="left" rowspan="1" colspan="1"> RV (mm) </td>
              <td rowspan="1" colspan="1"> 23 </td>
              <td rowspan="1" colspan="1"> 19.1 </td>
              <td rowspan="1" colspan="1"> 14.7 </td>
            </tr>
            <tr align="center">
              <td align="left" rowspan="1" colspan="1"> LVEDV (mL/m<sup>2</sup>) </td>
              <td rowspan="1" colspan="1"> 208 </td>
              <td rowspan="1" colspan="1"> 122 </td>
              <td rowspan="1" colspan="1"> 95 </td>
            </tr>
            <tr align="center">
              <td align="left" rowspan="1" colspan="1"> LVESV (mL/m<sup>2</sup>) </td>
              <td rowspan="1" colspan="1"> 168 </td>
              <td rowspan="1" colspan="1"> 51.6 </td>
              <td rowspan="1" colspan="1"> 48.7 </td>
            </tr>
            <tr align="center">
              <td align="left" rowspan="1" colspan="1"> LVEF (%) </td>
              <td rowspan="1" colspan="1"> 19 </td>
              <td rowspan="1" colspan="1"> 32-43 </td>
              <td rowspan="1" colspan="1"> 60 </td>
            </tr>
            <tr align="center">
              <td align="left" rowspan="1" colspan="1"> BNP (pg/mL) </td>
              <td rowspan="1" colspan="1"> 641 </td>
              <td rowspan="1" colspan="1"> 15 </td>
              <td rowspan="1" colspan="1"> 42 </td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>HR (bpm): heart rate (beats per minute); SaO<sub>2</sub>: oxygen saturation;
RV: right ventricle; LVEDV: left ventricular end-diastolic volume; LVESV: left
ventricular end-systolic volume; LVEF: left ventricular ejection fraction; BNP:
brain natriuretic peptide.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>We report for the first time the case of a male patient at school age with noncompaction
cardiomyopathy and myocardial dysfunction refractory to conventional clinical treatment,
whose clinical, laboratory and imaging parameters significantly improved after the
addition of a PDE-5 inhibitor (sildenafil) to the baseline drug treatment.</p>
      <p>Noncompaction cardiomyopathy was first described in 1932, on autopsy. It is a
heterogeneous disease with reserved prognosis. Its treatment is based on the progression
to systolic heart failure in the presence of thromboembolic phenomena or arrhythmias
secondary to LV impairment. Isolated noncompaction of the myocardium can be identified
from childhood to adulthood, occurring in both sexes<sup><xref rid="r06" ref-type="bibr">6</xref></sup>.</p>
      <p>The prognosis is extremely variable, the complications being considerably less frequent
in the pediatric age group<sup><xref rid="r07" ref-type="bibr">7</xref></sup>. In an
adult case series, approximately 60% had sudden death or underwent heart transplantation
six years within the diagnosis<sup><xref rid="r01" ref-type="bibr">1</xref></sup>.
Similarly, in another case series, 47% of 34 adults with isolated noncompaction
cardiomyopathy had the same outcome in a follow-up of 44 &#xB1; 39 months<sup><xref rid="r02" ref-type="bibr">2</xref></sup>.</p>
      <p>Phosphodiesterase type 5 is a specific enzyme that catalyzes the GMPc hydrolysis in
several tissues, acting on the metabolism of intracellular nitric oxide. Its inhibition
favors vasodilation, via permanence of intracellular GMPc<sup><xref rid="r08" ref-type="bibr">8</xref></sup>. However, in cardiac dysfunction, the beneficial effect
of PDE-5 inhibitors seems related to the deviation of the cascade and to the increase in
AMPc production, with an increase in intracellular calcium and contractility
improvement<sup><xref rid="r05" ref-type="bibr">5</xref></sup>. That effect has
also been related to the preservation of LV function and a reduction in fibrosis,
apoptosis and LV hypertrophy, via inhibition of the RhoA/Rho-kinase pathway. That
physiopathological pathway is associated with atherosclerosis, cardiac hypertrophy and
post-infarction remodeling<sup><xref rid="r08" ref-type="bibr">8</xref></sup>.</p>
      <p>Sildenafil is a selective PDE-5 inhibitor initially used to treat erectile dysfunction
and that has potential non urological applications<sup><xref rid="r04" ref-type="bibr">4</xref></sup>. According to Freitas Jr. et al<sup><xref rid="r09" ref-type="bibr">9</xref></sup>, the acute administration of sildenafil and sodium
nitroprusside has been associated with reverse cardiac remodeling, a reduction in right
cardiac chambers and an improvement in biventricular cardiac function<sup><xref rid="r09" ref-type="bibr">9</xref></sup>. The use of sildenafil improves oxygen
uptake, cardiac index, depression, and quality of life, and reduces aortic stiffness and
systemic vascular resistance in patients with CHF. Bocchi et al<sup><xref rid="r05" ref-type="bibr">5</xref></sup> have shown that, during exercise, the use
of sildenafil improved physical capacity, the attenuation of heart rate increase and its
reduction during recovery, on the treadmill exercise test<sup><xref rid="r05" ref-type="bibr">5</xref></sup>. G&#xF3;mez-S&#xE1;nchez et al<sup><xref rid="r10" ref-type="bibr">10</xref></sup> and Freitas Jr. et al<sup><xref rid="r09" ref-type="bibr">9</xref></sup> have shown that one single sublingual dose of sildenafil (100 mg)
was effective and safe to reduce pulmonary pressure and its variables during the
vascular reactivity test prior to heart transplantation, evidencing that, in addition to
a significant reduction in the pulmonary artery systolic pressure and in pulmonary and
systemic resistances, there was an increase in cardiac output and minimal effect on the
systemic circulation<sup><xref rid="r09" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup>.</p>
      <p>Sildenafil has not been approved for routine use in the pediatric population, except for
treating pulmonary arterial hypertension. However, the lack of other therapies that
could contribute to improve the patient's functional class and revert his heart failure
motivated the off-label use.</p>
      <p>Although greater extrapolations cannot be performed based on one single case report,
ours suggests that sildenafil might play an important role in the treatment of CHF in
the pediatric population, even in the absence of pulmonary arterial hypertension. This
emphasizes the need for studies designed for that purpose in that specific population.
</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>
<bold>Potential Conflict of Interest</bold>
</p>
        <p>No potential conflict of interest relevant to this article was reported.</p>
      </fn>
      <fn fn-type="con">
        <p>
<bold>Author contributions</bold>
</p>
        <p>Conception and design of the research: Fontes SRF, Elias PF, Souza R, Jatene IB.
Acquisition of data: Redondo ACC, Fuenmayor G, Shiraishi KS, Fontes SRF, Elias PF.
Analysis and interpretation of the data: Redondo ACC, Fuenmayor G, Shiraishi KS.
Statistical analysis: Redondo ACC, Fuenmayor G, Shiraishi KS, Souza R. Writing of the
manuscript: Redondo ACC, Fuenmayor G, Souza R. Critical revision of the manuscript
for intellectual content: Redondo ACC, Fuenmayor G, Fontes SRF, Elias PF, Souza R,
Jatene IB.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>
<bold>Sources of Funding</bold>
</p>
        <p>There were no external funding sources for this study.</p>
      </fn>
      <fn fn-type="other">
        <p>
<bold>Study Association</bold>
</p>
        <p>This study is not associated with any post-graduation program.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Madriago</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Silberback</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Heart failure in infants and children</article-title>
          <source>Pediatr Rev</source>
          <year>2010</year>
          <volume>31</volume>
          <issue>1</issue>
          <fpage>4</fpage>
          <lpage>12</lpage>
          <comment>Erratum in Pediatr Rev. 2010;31(4):158.</comment>
          <pub-id pub-id-type="pmid">20048034</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zambrano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Marshalko</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hui</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Isolated noncompaction of the ventricular myocardium: clinical and
molecular aspects of a rare cardiomyopathy</article-title>
          <source>Lab Invest</source>
          <year>2002</year>
          <volume>82</volume>
          <issue>2</issue>
          <fpage>117</fpage>
          <lpage>122</lpage>
          <pub-id pub-id-type="pmid">11850525</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosa</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Salemi</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Alexandre</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Noncompaction cardiomyopathy - a current view</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2011</year>
          <volume>97</volume>
          <issue>1</issue>
          <fpage>e13</fpage>
          <lpage>e19</lpage>
          <pub-id pub-id-type="pmid">21894393</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kukreja</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Salloum</surname>
              <given-names>FN</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Koka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ockaili</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Xi</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular
diseases</article-title>
          <source>Exp Clin Cardiol</source>
          <year>2011</year>
          <volume>16</volume>
          <issue>4</issue>
          <fpage>e30</fpage>
          <lpage>e35</lpage>
          <pub-id pub-id-type="pmid">22131856</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Guimaraes</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mocelin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bacal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bellotti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ramires</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Sildenafil effects on exercise, neurohormonal activation, and erectile
dysfunction in congestive heart failure: a double-blind, placebo-controlled,
randomized study, followed by a prospective treatment for erectile
dysfunction</article-title>
          <source>Circulation</source>
          <year>2002</year>
          <volume>106</volume>
          <issue>9</issue>
          <fpage>1097</fpage>
          <lpage>1103</lpage>
          <pub-id pub-id-type="pmid">12196335</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oechslin</surname>
              <given-names>EN</given-names>
            </name>
            <name>
              <surname>Attenhofer Jost</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Rojas</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Jenni</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Long-term follow-up of 34 adults with isolated left ventricular
noncompaction: a distinct cardiomyopathy with poor prognosis</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2000</year>
          <volume>36</volume>
          <issue>2</issue>
          <fpage>493</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="pmid">10933363</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ichida</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hamamichi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Miyawaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kamiya</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Akagi</surname>
              <given-names>T</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Clinical features of isolated noncompaction of the ventricular
myocardium: long-term clinical course, hemodynamic properties, and genetic
background</article-title>
          <source>J Am Coll Cardiol</source>
          <year>1999</year>
          <volume>34</volume>
          <issue>1</issue>
          <fpage>233</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="pmid">10400016</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Comstock</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stecher</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Kloner</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Cardiac uses of phosphodiesterase-5 inhibitors</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2012</year>
          <volume>59</volume>
          <issue>1</issue>
          <fpage>9</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="pmid">22192662</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freitas</surname>
              <given-names>AF</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Bacal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>Jde L</given-names>
              <suffix>J&#xFA;nior</suffix>
            </name>
            <name>
              <surname>Fiorelli</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>LF</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title> Sildenafil vs. sodium before nitroprusside for the pulmonary
hypertension reversibility test before cardiac transplantation</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2012</year>
          <volume>99</volume>
          <issue>3</issue>
          <fpage>848</fpage>
          <lpage>856</lpage>
          <pub-id pub-id-type="pmid">22898992</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Angel G&#xF3;mez-S&#xE1;nchez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saenz De La Calzada</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Escribano Sub&#xED;as</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Francisco Delgado Jim&#xE9;nez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>L&#xE1;zaro Salvador</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Albarr&#xE1;n Gonz&#xE1;lez</surname>
              <given-names>A</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Pilot assessment of the response of several pulmonary hemodynamic
variables to sublingual sildenafil in candidates for heart
transplantation</article-title>
          <source>Eur J Heart Fail</source>
          <year>2004</year>
          <volume>6</volume>
          <issue>5</issue>
          <fpage>615</fpage>
          <lpage>617</lpage>
          <pub-id pub-id-type="pmid">15302010</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
